Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average) (2023 - 2025)

Compass Therapeutics' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $157.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 14.77% year-over-year to $157.7 million; the TTM value through Dec 2025 reached $157.7 million, up 14.77%, while the annual FY2025 figure was $157.7 million, 14.77% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $157.7 million at Compass Therapeutics, down from $168.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $168.8 million in Q3 2025 and bottomed at $126.4 million in Q1 2023.
  • The 3-year median for Shares Outstanding (Weighted Average) is $137.4 million (2024), against an average of $138.2 million.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 22.93% in 2025 against a maximum downside of 0.49% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $127.0 million in 2023, then increased by 8.17% to $137.4 million in 2024, then increased by 14.77% to $157.7 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Shares Outstanding (Weighted Average) are $157.7 million (Q4 2025), $168.8 million (Q3 2025), and $138.3 million (Q2 2025).